Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-ee6aef82d41445c7c0958abae70ec0df"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-ee6aef82d41445c7c0958abae70ec0df"/>
<resource>
<Composition>
<id value="composition-en-ee6aef82d41445c7c0958abae70ec0df"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-ee6aef82d41445c7c0958abae70ec0df"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-ee6aef82d41445c7c0958abae70ec0df</b></p><a name="composition-en-ee6aef82d41445c7c0958abae70ec0df"> </a><a name="hccomposition-en-ee6aef82d41445c7c0958abae70ec0df"> </a><a name="composition-en-ee6aef82d41445c7c0958abae70ec0df-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/30 tablets: EU/1/09/579/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - repaglinide</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="30 tablets: EU/1/09/579/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpee6aef82d41445c7c0958abae70ec0df"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - repaglinide"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Repaglinide Krka is and what it is used for</li><li>What you need to know before you take Repaglinide Krka</li><li>How to take Repaglinide Krka</li><li>Possible side effects</li><li>How to store Repaglinide Krka</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What repaglinide is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What repaglinide is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Repaglinide Krka is an oral antidiabetic medicine containing repaglinide which helps your pancreas produce more insulin and thereby lower your blood sugar (glucose). Type 2 diabetes is a disease in which your pancreas does not make enough insulin to control the sugar in your blood or where your body does not respond normally to the insulin it produces. Repaglinide Krka is used to control type 2 diabetes in adults as an add-on to diet and exercise: treatment is usually started if diet, exercise and weight reduction alone have not been able to control (or lower) your blood sugar. Repaglinide Krka can also be given with metformin, another medicine for diabetes. Repaglinide Krka has been shown to lower the blood sugar, which helps to prevent complications from your diabetes.</p></div>
</text>
</section>
<section>
<title
value="2. What you need to know before you take repaglinide"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take repaglinide"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Repaglinide Krka</p><p>if you are allergic to repaglinide or any of the other ingredients of this medicine (listed in section 6).</p><p>if you have type 1 diabetes.</p><p>if the acid level in your blood is raised (diabetic ketoacidosis).</p><p>if you have a severe liver disease.</p><p>if you take gemfibrozil (a medicine used to lower increased fat levels in the blood). Warning and precautions Talk to your doctor before taking Repaglinide Krka:</p><p>if you have liver problems. Repaglinide Krka is not recommended in patients with moderate liver disease. Repaglinide Krka should not be taken if you have a severe liver disease (see Do not take Repaglinide Krka).</p><p>if you have kidney problems. Repaglinide Krka should be taken with caution.</p><p>if you are about to have major surgery or you have recently suffered a severe illness or infection. At such times diabetic control may be lost.</p><p>if you are under 18 or over 75 years of age. Repaglinide Krka is not recommended. It has not been studied in these age groups. Talk to your doctor if any of the above applies to you. Repaglinide Krka may not be suitable for you. Your doctor will advise you. Children and adolescents Do not take this medicine if you are under 18 years of age. If you get a hypo (low blood sugar) You may get a hypo (short for hypoglycaemia) if your blood sugar gets too low. This may happen:</p><p>if you take too much Repaglinide Krka</p><p>if you exercise more than usual</p><p>if you take other medicines or suffer from liver or kidney problems (see other sections of</p></div>
</text>
</section>
<section>
<title value="3. How to take repaglinide"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take repaglinide"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>The warning signs of a hypo may come on suddenly and can include: cold sweat, cool pale skin, headache, rapid heart beat, feeling sick, feeling very hungry, temporary changes in vision, drowsiness, unusual tiredness and weakness, nervousness or tremor, feeling anxious, feeling confused, difficulty in concentrating. If your blood sugar is low or you feel a hypo coming on eat glucose tablets or a high sugar snack or drink, then rest. When symptoms of hypoglycaemia have disappeared or when blood sugar levels are stabilised continue repaglinide treatment. Tell people you have diabetes and that if you pass out (become unconscious) due to a hypo, they must turn you on your side and get medical help straight away. They must not give you any food or drink. It could choke you. If severe hypoglycaemia is not treated, it can cause brain damage (temporary or permanent) and even death. If you have a hypo that makes you pass out, or a lot of hypos, talk to your doctor. The amount of Repaglinide Krka, food or exercise may need to be adjusted. If your blood sugar gets too high Your blood sugar may get too high (hyperglycaemia). This may happen:</p><p>if you take too little Repaglinide Krka,</p><p>if you have an infection or a fever,</p><p>if you eat more than usual,</p><p>if you exercise less than usual. The warning signs of too high blood sugar appear gradually. They include: increased urination, feeling thirsty, dry skin and dry mouth. Talk to your doctor. The amount of Repaglinide Krka, food or exercise may need to be adjusted. Other medicines and Repaglinide Krka Tell your doctor or pharmacist if you are taking or have recently taken any other medicines. You can take Repaglinide Krka with metformin, another medicine for diabetes, if your doctor prescribes it. If you take gemfibrozil (used to lower increased fat levels in the blood) you should not take Repaglinide Krka. Your body s response to Repaglinide Krka may change if you take other medicines, especially these:</p><p>Monoamine oxidase inhibitors (MAOI) (used to treat depression).</p><p>Beta blockers (used to treat high blood pressure or heart conditions).</p><p>ACE-inhibitors (used to treat heart conditions).</p><p>Salicylates (e.g. aspirin).</p><p>Octreotide (used to treat cancer).</p><p>Nonsteroidal anti-inflammatory drugs (NSAID) (a type of painkillers).</p><p>Steroids (anabolic steroids and corticosteroids used for anaemia or to treat inflammation).</p><p>Oral contraceptives (birth control pills).</p><p>Thiazides (diuretics or water pills ).</p><p>Danazol (used to treat breast cysts and endometriosis).</p><p>Thyroid products (used to treat low levels of thyroid hormones).</p><p>Sympathomimetics (used to treat asthma).</p><p>Clarithromycin, trimethoprim, rifampicin (antibiotic medicines).</p><p>Itraconazole, ketokonazole (antifungal medicines).</p><p>Gemfibrozil (used to treat high blood fats).</p><p>Ciclosporin (used to suppress the immune system).</p><p>Deferasirox (used to reduce chronic iron overload).</p><p>Clopidogrel (prevents blood clots).</p><p>Phenytoin, carbamazepine, phenobarbital (used to treat epilepsy).</p><p>St.John s wort (herbal medicine). Repaglinide Krka with alcohol Alcohol can change the ability of Repaglinide Krka to reduce the blood sugar. Watch for signs of a hypo. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. You should not take Repaglinide Krka if you are pregnant or you are planning to become pregnant. You should not take Repaglinide Krka if you are breast-feeding. Driving and using machines Your ability to drive or use a machine may be affected if your blood sugar is low or high. Bear in mind that you could endanger yourself or others. Please ask your doctor whether you can drive a car if you:</p><p>have frequent hypos,</p><p>have few or no warning signs of hypos. Repaglinide Krka contains sodium This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. Your doctor will work out your dose.</p><p>The normal starting dose is 0.5 mg before each main meal. Swallow the tablets with a glass of water immediately before or up to 30 minutes before each main meal.</p><p>The dose may be adjusted by your doctor by up to 4 mg to be taken immediately before or up to 30 minutes before each main meal. The maximum recommended daily dose is 16 mg. Do not take more Repaglinide Krka than your doctor has recommended. If you take more Repaglinide Krka than you should If you take too many tablets, your blood sugar may become too low, leading to a hypo. Please see If you get a hypo on what a hypo is and how to treat it. If you forget to take Repaglinide Krka If you miss a dose, take the next dose as usual. Do not take a double dose to make up for a forgotten tablet. If you stop taking Repaglinide Krka Be aware that the desired effect is not achieved if you stop taking Repaglinide Krka. Your diabetes may get worse. If any change of your treatment is necessary contact your doctor first. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="5. How to store repaglinide"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store repaglinide"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Hypoglycaemia The most frequent side effect is hypoglycaemia which may affect up to 1 in 10 people (see If you get a hypo in section 2). Hypoglycaemic reactions are generally mild/moderate but may occasionally develop into hypoglycaemic unconsciousness or coma. If this happens, medical assistance is needed immediately. Allergy Allergy is very rare (may affect up to 1 in 10,000 people). Symptoms such as swelling, difficulty in breathing, rapid heartbeat, feeling dizzy and sweating could be signs of anaphylactic reaction. Contact a doctor immediately. Other side effects Common (may affect up to 1 in 10 people):</p><p>Stomach pain</p><p>Diarrhoea Rare (may affect up to 1 in 1,000 people):</p><p>Acute coronary syndrome (but it may not be due to the medicine) Very rare (may affect up to 1 in 10,000 people):</p><p>Vomiting</p><p>Constipation</p><p>Visual disturbances</p><p>Severe liver problems, abnormal liver function, such as increased liver enzymes in your blood. Not known (frequency cannot be estimated from the available data)</p><p>Hypersensitivity (such as rash, itchy skin, reddening of the skin, swelling of the skin)</p><p>Feeling sick (nausea) Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the blister and outer carton. The expiry date refers to the last day of that month. Store in the original package in order to protect from light. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpee6aef82d41445c7c0958abae70ec0df"/>
<resource>
<MedicinalProductDefinition>
<id value="mpee6aef82d41445c7c0958abae70ec0df"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpee6aef82d41445c7c0958abae70ec0df"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpee6aef82d41445c7c0958abae70ec0df</b></p><a name="mpee6aef82d41445c7c0958abae70ec0df"> </a><a name="hcmpee6aef82d41445c7c0958abae70ec0df"> </a><a name="mpee6aef82d41445c7c0958abae70ec0df-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/30 tablets: EU/1/09/579/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Repaglinide Krka 0.5 mg tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="30 tablets: EU/1/09/579/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Repaglinide Krka 0.5 mg tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
